Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy

Stacey Schultz-Cherry; Maureen A. Mcgargill; Paul G. Thomas; Jeremie H. Estepp; Aditya H. Gaur; E. Kaitlynn Allen; Kim J. Allison; Li Tang; Richard J. Webby; Sean D. Cherry; Chun Yang Lin; Thomas Fabrizio; Elaine I. Tuomanen; Joshua Wolf; Ericka Kirkpatrick Roubidoux; Pamela Freiden; Tomi Mori; Diego R. Hijano; Hana Hakim; David C. Brice; Ashley Castellaw; Florian Krammer; David E. Wittman; Jason Hodges; Ronald H. Dallas; Valerie Cortez; Ana Vazquez-Pagan; Resha Bajracharya; Brandi L. Clark; Lee Ann Van De Velde; Walid Awad; Taylor L. Wilson; Allison M. Kirk; Randall T. Hayden; James Hoffman; Jamie Russell-Bell; James Sparks

doi:10.1093/ofid/ofab420

Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy

Stacey Schultz-Cherry, Maureen A. Mcgargill, Paul G. Thomas, Jeremie H. Estepp, Aditya H. Gaur, E. Kaitlynn Allen, Kim J. Allison, Li Tang, Richard J. Webby, Sean D. Cherry, Chun Yang Lin, Thomas Fabrizio, Elaine I. Tuomanen, Joshua Wolf, Ericka Kirkpatrick Roubidoux, Pamela Freiden, Tomi Mori, Diego R. Hijano, Hana Hakim, David C. BriceAshley Castellaw, Florian Krammer, David E. Wittman, Jason Hodges, Ronald H. Dallas, Valerie Cortez, Ana Vazquez-Pagan, Resha Bajracharya, Brandi L. Clark, Lee Ann Van De Velde, Walid Awad, Taylor L. Wilson, Allison M. Kirk, Randall T. Hayden, James Hoffman, Jamie Russell-Bell, James Sparks

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference"might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. Trial registration.: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.

Original language	English
Article number	ofab420
Journal	Open Forum Infectious Diseases
Volume	8
Issue number	9
DOIs	https://doi.org/10.1093/ofid/ofab420
State	Published - 1 Sep 2021

Keywords

Antibody
COVID-19
SARS-CoV-2
bamlanivimab
vaccine failure

Access to Document

10.1093/ofid/ofab420

Cite this

Schultz-Cherry, S., Mcgargill, M. A., Thomas, P. G., Estepp, J. H., Gaur, A. H., Allen, E. K., Allison, K. J., Tang, L., Webby, R. J., Cherry, S. D., Lin, C. Y., Fabrizio, T., Tuomanen, E. I., Wolf, J., Kirkpatrick Roubidoux, E., Freiden, P., Mori, T., Hijano, D. R., Hakim, H., ... Sparks, J. (2021). Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy. Open Forum Infectious Diseases, 8(9), Article ofab420. https://doi.org/10.1093/ofid/ofab420

@article{273d471de3794c269018e2059c2e608a,

title = "Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy",

abstract = "The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and {"}antibody interference{"}might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. Trial registration.: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.",

keywords = "Antibody, COVID-19, SARS-CoV-2, bamlanivimab, vaccine failure",

author = "Stacey Schultz-Cherry and Mcgargill, {Maureen A.} and Thomas, {Paul G.} and Estepp, {Jeremie H.} and Gaur, {Aditya H.} and Allen, {E. Kaitlynn} and Allison, {Kim J.} and Li Tang and Webby, {Richard J.} and Cherry, {Sean D.} and Lin, {Chun Yang} and Thomas Fabrizio and Tuomanen, {Elaine I.} and Joshua Wolf and {Kirkpatrick Roubidoux}, Ericka and Pamela Freiden and Tomi Mori and Hijano, {Diego R.} and Hana Hakim and Brice, {David C.} and Ashley Castellaw and Florian Krammer and Wittman, {David E.} and Jason Hodges and Dallas, {Ronald H.} and Valerie Cortez and Ana Vazquez-Pagan and Resha Bajracharya and Clark, {Brandi L.} and {Van De Velde}, {Lee Ann} and Walid Awad and Wilson, {Taylor L.} and Kirk, {Allison M.} and Hayden, {Randall T.} and James Hoffman and Jamie Russell-Bell and James Sparks",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s).",

year = "2021",

month = sep,

day = "1",

doi = "10.1093/ofid/ofab420",

language = "English",

volume = "8",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "9",

}

Schultz-Cherry, S, Mcgargill, MA, Thomas, PG, Estepp, JH, Gaur, AH, Allen, EK, Allison, KJ, Tang, L, Webby, RJ, Cherry, SD, Lin, CY, Fabrizio, T, Tuomanen, EI, Wolf, J, Kirkpatrick Roubidoux, E, Freiden, P, Mori, T, Hijano, DR, Hakim, H, Brice, DC, Castellaw, A, Krammer, F, Wittman, DE, Hodges, J, Dallas, RH, Cortez, V, Vazquez-Pagan, A, Bajracharya, R, Clark, BL, Van De Velde, LA, Awad, W, Wilson, TL, Kirk, AM, Hayden, RT, Hoffman, J, Russell-Bell, J & Sparks, J 2021, 'Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy', Open Forum Infectious Diseases, vol. 8, no. 9, ofab420. https://doi.org/10.1093/ofid/ofab420

TY - JOUR

T1 - Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy

AU - Schultz-Cherry, Stacey

AU - Mcgargill, Maureen A.

AU - Thomas, Paul G.

AU - Estepp, Jeremie H.

AU - Gaur, Aditya H.

AU - Allen, E. Kaitlynn

AU - Allison, Kim J.

AU - Tang, Li

AU - Webby, Richard J.

AU - Cherry, Sean D.

AU - Lin, Chun Yang

AU - Fabrizio, Thomas

AU - Tuomanen, Elaine I.

AU - Wolf, Joshua

AU - Kirkpatrick Roubidoux, Ericka

AU - Freiden, Pamela

AU - Mori, Tomi

AU - Hijano, Diego R.

AU - Hakim, Hana

AU - Brice, David C.

AU - Castellaw, Ashley

AU - Krammer, Florian

AU - Wittman, David E.

AU - Hodges, Jason

AU - Dallas, Ronald H.

AU - Cortez, Valerie

AU - Vazquez-Pagan, Ana

AU - Bajracharya, Resha

AU - Clark, Brandi L.

AU - Van De Velde, Lee Ann

AU - Awad, Walid

AU - Wilson, Taylor L.

AU - Kirk, Allison M.

AU - Hayden, Randall T.

AU - Hoffman, James

AU - Russell-Bell, Jamie

AU - Sparks, James

PY - 2021/9/1

Y1 - 2021/9/1

N2 - The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference"might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. Trial registration.: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.

AB - The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference"might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting. Trial registration.: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.

KW - Antibody

KW - COVID-19

KW - SARS-CoV-2

KW - bamlanivimab

KW - vaccine failure

UR - http://www.scopus.com/inward/record.url?scp=85118239477&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofab420

DO - 10.1093/ofid/ofab420

M3 - Article

AN - SCOPUS:85118239477

SN - 2328-8957

VL - 8

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 9

M1 - ofab420

ER -

Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine after Recent COVID-19-Specific Monoclonal Antibody Therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this